Pinnacle Food Group Unveils Methanol-Free Breakthrough in Recombinant Human Lactoferrin Production

The latest update is out from Pinnacle Food Group Limited Class A ( (PFAI) ).

On April 15, 2026, Pinnacle Food Group Limited announced that its Hong Kong laboratory has created a first-generation recombinant yeast strain to produce human lactoferrin using a patented methanol-free Pichia fermentation method accessed via its collaboration with Bioboost. This platform, already validated at pilot scale for other proteins, removes the need for flammable methanol, cutting CapEx and safety risks while enabling high-purity production for infant nutrition, dietary supplement, and pharmaceutical uses, strengthening the company’s bid to become a leading B2B supplier of high-value biological ingredients.

The methanol-free fermentation breakthrough is expected to improve Pinnacle’s operational economics by reducing explosion-proof facility requirements and eliminating toxic residues in sensitive applications. By advancing a scalable, commercially ready precision fermentation platform targeting high-value proteins such as recombinant human lactoferrin, the company reinforces its position in the emerging bio-engineered ingredients market and supports its broader smart agriculture and synthetic biology growth strategy.

More about Pinnacle Food Group Limited Class A

Pinnacle Food Group Limited is a technology-driven company operating at the intersection of smart agriculture and bio-engineering, listed on Nasdaq under the symbol PFAI. It pursues a “Dual-Engine” strategy that combines Farming-as-a-Service solutions with precision fermentation and synthetic biology platforms to build more efficient and sustainable food systems for business customers.

Average Trading Volume: 11,850

Technical Sentiment Signal: Strong Buy

Current Market Cap: $45.28M

See more data about PFAI stock on TipRanks’ Stock Analysis page.